

eliminate existing barriers to treatment so that young women have access to high quality breast cancer treatment and care. Results will also be used to improve care and services provided to

young women diagnosed with breast cancer. Study findings will be disseminated through reports, presentations, and publications.

OMB approval is requested for one year. Participation is voluntary and there are no costs to respondents other than their time. The total estimated annualized burden hours are 1,241.

ESTIMATED TOTAL BURDEN HOURS

Type of respondent	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Sample 1—Breast cancer survivors recruited from state cancer registries.	Breast Cancer in Young Women Survey (Mail-in or web-based questionnaire).	1,200	1	22/60
Sample 2—Breast cancer survivors associated with advocacy groups (ineligibles).	Breast Cancer in Young Women Survey (Screener only).	25	1	2/60
Sample 2—Breast cancer survivors associated with advocacy groups (eligible and complete).	Breast Cancer in Young Women Survey (Screener and Web-based questionnaire).	2,000	1	24/60

Leroy A. Richardson,

Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2016-04013 Filed 2-24-16; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Healthcare Infection Control Practices Advisory Committee (HICPAC)

In accordance with section 10(a) (2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announce the following meeting for the aforementioned committee:

Times and Dates: 9:00 a.m.–5:00 p.m., EDT, March 31, 2016; 9:00 a.m.–12:00 p.m., EDT, April 1, 2016.

Place: Centers for Disease Control and Prevention, Global Communications Center, Building 19, Auditorium B, 1600 Clifton Road NE., Atlanta, Georgia, 30333.

Status: Open to the public, limited only by the space available. Please register for the meeting at www.cdc.gov/hicpac.

Purpose: The Committee is charged with providing advice and guidance to the Director, Division of Healthcare Quality Promotion, the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Director, CDC, the Secretary, Health and Human Services regarding (1) the practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions.

Matters for Discussion: The agenda will include updates on CDC's activities for prevention of healthcare associated infections (HAIs), updates on antimicrobial stewardship, an update on Draft Guideline for Prevention of Infections in Healthcare Personnel, chlorhexidine gluconate-impregnated dressings, and an update from the workgroup for considerations on endoscope reprocessing.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Erin Stone, M.S., HICPAC, Division of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road NE., Mailstop A-07, Atlanta, Georgia 30333. Telephone (404) 639-4045. Email: hicpac@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Claudette Grant,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2016-03929 Filed 2-24-16; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, Announces the Following Meeting

Name: ICD-10 Coordination and Maintenance (C&M) Committee meeting.

Time and Date: 9:00 a.m.–5:00 p.m., EST, March 9–10, 2016.

Place: Centers for Medicare and Medicaid Services (CMS) Auditorium,

7500 Security Boulevard, Baltimore, Maryland 21244.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 240 people. We will be broadcasting the meeting live via Webcast at <http://www.cms.gov/live/>.

Security Considerations: Due to increased security requirements CMS has instituted stringent procedures for entrance into the building by non-government employees. Attendees will need to present valid government-issued picture identification, and sign-in at the security desk upon entering the building.

Attendees who wish to attend the March 9–10, 2016 ICD-10-CM C&M meeting must submit their name and organization by March 1, 2016 for inclusion on the visitor list. This visitor list will be maintained at the front desk of the CMS building and used by the guards to admit visitors to the meeting.

Participants who attended previous Coordination and Maintenance meetings will no longer be automatically added to the visitor list. You must request inclusion of your name prior to each meeting you wish attend.

Please register to attend the meeting on-line at: <http://www.cms.hhs.gov/apps/events/>. Please contact Mady Hue (410-786-4510 or Marilu.hue@cms.hhs.gov), for questions about the registration process.

Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Tenth Revision, Clinical Modification and ICD-10 Procedure Coding System.

Matters for Discussion: Agenda items include: March 9–10, 2016.

ICD-10-PCS Topics

Removal of Thrombus and Emboli
 Insertion of Endobronchial Coils
 Hematopoietic Cell Transplant Donor
 Fluorescence Vascular Angiography
 (FVA) (FVA)
 Rapid Deployment Aortic Valve
 Replacement Replacement
 Branch Endograft Repair of Common
 Iliac Aneurysm
 Total Anomalous Pulmonary Venous
 Return
 Administration of Andexanet Alfa
 Injection for I.V. Infusion
 Administration of VISTOGARD (uridine
 triacetate)
 Mechanical Embolectomy with Stent
 Retriever Retrieve
 Intracranial Aneurysm Procedure Using
 Flow Diverter Stent
 Spinal Bracing and Distraction System
 Interbody Spinal Fusion with Nano-
 Textured Surface
 Therapeutic Artificial Rupture of
 Membranes
 Application of Biologic Wound Matrix
 (MircoDERM)
 Oxidized Zirconium on Polyethylene
 Bearing Surfaces
 GEM Structure and Update Requests
 Addenda and Key Updates

ICD-10-CM Diagnosis Topics

Antenatal Screening
Clostridium difficile
 Congenital Sacral Dimple
 Exercise Counseling
 Hepatic Encephalopathy
 Lacunar Infarction
 Pediatric Cryptorchidism
 Post-operative Seroma
 Soft Tissue Sarcoma
 Spinal Stenosis
 Temporomandibular Joint Disorders
 Zika Virus Infection
 ICD-10-CM Addendum

Agenda items are subject to change as priorities dictate.

Note: CMS and NCHS no longer provide paper copies of handouts for the meeting. Electronic copies of all meeting materials will be posted on the CMS and NCHS Web sites prior to the meeting at <http://www.cms.hhs.gov/ICD9ProviderDiagnosticCodes/03meetings.asp#TopOfPage> and http://www.cdc.gov/nchs/icd/icd9cm_maintenance.htm

Contact Persons for Additional Information: Donna Pickett, Medical Systems Administrator, Classifications and Public Health Data Standards Staff, NCHS, 3311 Toledo Road, Hyattsville, Maryland 20782, email dfp4@cdc.gov, telephone 301-458-4434 (diagnosis); Mady Hue, Health Insurance Specialist, Division of Acute Care, CMS, 7500 Security Boulevard, Baltimore, Maryland 21244, email marilu.hue@cms.hhs.gov, telephone 410-786-4510 (procedures).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.

Claudette Grant,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2016-03930 Filed 2-24-16; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), and pursuant to the requirements of 42 CFR 83.15(a), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

Times and Dates: 9:00 a.m.–5:00 p.m., Eastern Time, March 23, 2015; 8:15 a.m.–12:30 p.m., Eastern Time, March 24, 2015.

Public Comment Time and Date: 5:00 p.m.–6:00 p.m. *, Eastern Time, March 23, 2015.

* Please note that the public comment period may end before the time indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend the public comment session at the start time listed.

Place: Hilton Tampa Airport Westshore, 2225 N. Lois Avenue, Tampa, Florida 33607; Phone: (800) 445-8667; Fax: (813) 872-0603. Audio Conference Call via FTS Conferencing. The USA toll-free, dial-in number is 1-866-659-0537 with a pass code of 9933701. Live Meeting CONNECTION: <https://www.livemeeting.com/cc/cdc/join?id=GHFDT9&role=attend&pw=ABRWH>; Meeting ID: GHFDT9; Entry Code: ABRWH.

Status: Open to the public, limited only by the space available. The meeting space accommodates approximately 100 people.

Background: The Advisory Board was established under the Energy Employees Occupational Illness Compensation

Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines which have been promulgated by the Department of Health and Human Services (HHS) as a final rule, advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule, advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program, and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC).

In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to the CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, and will expire on August 3, 2017.

Purpose: This Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advising the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class.

Matters for Discussion: The agenda for the Advisory Board meeting includes: NIOSH Program Update; Department of Labor Program Update; Department of Energy Program Update; Report by the Dose Reconstruction Review Methods Work Group; Dose Reconstruction Report to the Secretary; SEC Petitions Update; Site Profile review for: Pinellas Plant (Clearwater, Florida); SEC petitions for: Lawrence Livermore National Laboratory (1974–1995; Livermore, California), Idaho National Laboratory (1949–1970; Scoville, Idaho), and Argonne National Laboratory West (1951–1979; Scoville, Idaho); and Board Work Sessions.

The agenda is subject to change as priorities dictate.

In the event an individual cannot attend, written comments may be